Cost-effectiveness of linezolid versus vancomycin in the treatment of nosocomial pneumonia in Argentina

被引：0
|
作者：
Aiello, EC
Barcelona, LI
De Vedia, L
Stamboulian, D
机构：
[1] Pfizer Argentina, Buenos Aires, DF, Argentina
[2] FUNCEI, Buenos Aires, DF, Argentina
[3] Hosp Muniz, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A155 / A156
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA IN JAMAICA
    Garita, M.
    Nicholson, A.
    Cuesta, G.
    Mould, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A352 - A352
  • [2] Cost-effectiveness of linezolid versus vancomycin in the treatment of nosocomial pneumonia suspected to be caused by methicillin-resistant Staphylococcus aureus in Spain
    Leon, C.
    Gomez, Mateos J. M.
    Catala, R.
    Vazquez, M. J.
    Alvarez, Rocha L.
    Najera, M. D.
    Rubio-Terres, C.
    Garcia, M.
    Escudero, Lopez-Cepero E.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A439 - A440
  • [3] Cost-effectiveness of linezolid versus vancomycin in suspected methicillin-resistant staphylococcus aureus in nosocomial pneumonia in Germany
    Grünewald, T
    De Cock, E
    Sorensen, SV
    Baker, TM
    Resch, A
    Hardewig, J
    Duttagupta, S
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 758 - 758
  • [4] COST-EFFECTIVENESS EVALUATION OF THE USE OF LINEZOLID IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA IN MEXICO
    Vargas-Valencia, J. J.
    Sotelo-Guzman, M.
    Diaz-Ponce, H.
    Galindo-Suarez, R. M.
    Mucino-Ortega, E.
    Mould-Quevedo, J. F.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A559 - A559
  • [5] Cost-effectiveness analysis of linezolid versus vancomycin in the treatment of ventilator-associated pneumonia in Spain
    Grau, S
    Alvarez-Lerma, F
    De la Fuente, S
    Neipp, R
    Rubio-Terres, C
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 759 - 759
  • [6] Linezolid versus vancomycin for MRSA nosocomial pneumonia
    不详
    [J]. FUTURE MICROBIOLOGY, 2010, 5 (12) : 1763 - 1763
  • [7] Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
    Mullins, C. Daniel
    Kuznik, Andreas
    Shaya, Fadia T.
    Obeidat, Nour A.
    Levine, Andrew R.
    Liu, Larry Z.
    Wong, Winston
    [J]. CLINICAL THERAPEUTICS, 2006, 28 (08) : 1184 - 1198
  • [8] Linezolid versus vancomycin cost in the treatment of staphylococcal pneumonia
    Huon, J. F.
    Boutoille, D.
    Caillon, J.
    Orain, J.
    Crochette, N.
    Potel, G.
    Abgueguen, P.
    Moal, F.
    Navas, D.
    [J]. MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (03): : 252 - 256
  • [9] Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain
    Grau, S
    Alvarez-Lerma, F
    Del Castillo, A
    Neipp, R
    Rubio-Terrés, C
    [J]. JOURNAL OF CHEMOTHERAPY, 2005, 17 (02) : 203 - 211
  • [10] A COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN FOR VENTILATOR-ASSOCIATED PNEUMONIA PATIENTS IN PANAMA
    Lutz, M. A.
    Villalobos, D.
    Morales, G.
    Cuesta, G.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A274 - A274
12345